Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
DCTH's Cash to Debt is ranked higher than
98% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. DCTH: No Debt )
Ranked among companies with meaningful Cash to Debt only.
DCTH' s 10-Year Cash to Debt Range
Min: 1.97  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.76
DCTH's Equity to Asset is ranked higher than
71% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DCTH: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
DCTH' s 10-Year Equity to Asset Range
Min: 0.61  Med: 0.77 Max: 0.84
Current: 0.76
0.61
0.84
Interest Coverage No Debt
DCTH's Interest Coverage is ranked higher than
97% of the 370 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 933.44 vs. DCTH: No Debt )
Ranked among companies with meaningful Interest Coverage only.
DCTH' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: -16.20
M-Score: -3.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1492.19
DCTH's Operating margin (%) is ranked lower than
97% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. DCTH: -1492.19 )
Ranked among companies with meaningful Operating margin (%) only.
DCTH' s 10-Year Operating margin (%) Range
Min: -15569.65  Med: -4179.62 Max: -1805.8
Current: -1492.19
-15569.65
-1805.8
Net-margin (%) -1296.01
DCTH's Net-margin (%) is ranked lower than
97% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. DCTH: -1296.01 )
Ranked among companies with meaningful Net-margin (%) only.
DCTH' s 10-Year Net-margin (%) Range
Min: -14990.75  Med: -3838.48 Max: -1625.91
Current: -1296.01
-14990.75
-1625.91
ROE (%) -70.81
DCTH's ROE (%) is ranked lower than
91% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. DCTH: -70.81 )
Ranked among companies with meaningful ROE (%) only.
DCTH' s 10-Year ROE (%) Range
Min: -224.96  Med: -90.08 Max: -29.56
Current: -70.81
-224.96
-29.56
ROA (%) -55.80
DCTH's ROA (%) is ranked lower than
94% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. DCTH: -55.80 )
Ranked among companies with meaningful ROA (%) only.
DCTH' s 10-Year ROA (%) Range
Min: -157.86  Med: -70.64 Max: -27.27
Current: -55.8
-157.86
-27.27
ROC (Joel Greenblatt) (%) -839.22
DCTH's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. DCTH: -839.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DCTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -194983.33  Med: -4637.02 Max: -161.78
Current: -839.22
-194983.33
-161.78
EBITDA Growth (3Y)(%) -43.20
DCTH's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. DCTH: -43.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DCTH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -43.2  Med: -1.60 Max: 56.5
Current: -43.2
-43.2
56.5
EPS Growth (3Y)(%) -44.80
DCTH's EPS Growth (3Y)(%) is ranked lower than
92% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. DCTH: -44.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DCTH' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.8  Med: -7.45 Max: 93.9
Current: -44.8
-44.8
93.9
» DCTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DCTH Guru Trades in Q2 2014

Jim Simons 59,298 sh (New)
» More
Q3 2014

DCTH Guru Trades in Q3 2014

Jim Simons 161,798 sh (+172.86%)
» More
Q4 2014

DCTH Guru Trades in Q4 2014

Jim Simons 260,960 sh (+61.29%)
» More
Q1 2015

DCTH Guru Trades in Q1 2015

Jim Simons 345,098 sh (+32.24%)
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.70
DCTH's P/B is ranked higher than
92% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. DCTH: 0.70 )
Ranked among companies with meaningful P/B only.
DCTH' s 10-Year P/B Range
Min: 0.57  Med: 1.16 Max: 6.18
Current: 0.7
0.57
6.18
P/S 7.87
DCTH's P/S is ranked lower than
76% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. DCTH: 7.87 )
Ranked among companies with meaningful P/S only.
DCTH' s 10-Year P/S Range
Min: 6.75  Med: 43.80 Max: 1077.33
Current: 7.87
6.75
1077.33
EV-to-EBIT 0.34
DCTH's EV-to-EBIT is ranked higher than
99% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.91 vs. DCTH: 0.34 )
Ranked among companies with meaningful EV-to-EBIT only.
DCTH' s 10-Year EV-to-EBIT Range
Min: -2.5  Med: -0.10 Max: 0.5
Current: 0.34
-2.5
0.5
Current Ratio 4.73
DCTH's Current Ratio is ranked higher than
75% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. DCTH: 4.73 )
Ranked among companies with meaningful Current Ratio only.
DCTH' s 10-Year Current Ratio Range
Min: 0.58  Med: 7.06 Max: 67.13
Current: 4.73
0.58
67.13
Quick Ratio 4.66
DCTH's Quick Ratio is ranked higher than
79% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. DCTH: 4.66 )
Ranked among companies with meaningful Quick Ratio only.
DCTH' s 10-Year Quick Ratio Range
Min: 0.58  Med: 7.06 Max: 67.13
Current: 4.66
0.58
67.13
Days Inventory 520.48
DCTH's Days Inventory is ranked lower than
98% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. DCTH: 520.48 )
Ranked among companies with meaningful Days Inventory only.
DCTH' s 10-Year Days Inventory Range
Min: 669.79  Med: 717.41 Max: 5170.83
Current: 520.48
669.79
5170.83
Days Sales Outstanding 94.66
DCTH's Days Sales Outstanding is ranked lower than
65% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.51 vs. DCTH: 94.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
DCTH' s 10-Year Days Sales Outstanding Range
Min: 59.41  Med: 151.91 Max: 161.25
Current: 94.66
59.41
161.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.88
DCTH's Price/Net Cash is ranked higher than
98% of the 184 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.71 vs. DCTH: 0.88 )
Ranked among companies with meaningful Price/Net Cash only.
DCTH' s 10-Year Price/Net Cash Range
Min: 0.79  Med: 6.23 Max: 62.95
Current: 0.88
0.79
62.95
Price/Net Current Asset Value 0.79
DCTH's Price/Net Current Asset Value is ranked higher than
97% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. DCTH: 0.79 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DCTH' s 10-Year Price/Net Current Asset Value Range
Min: 0.72  Med: 5.76 Max: 44.4
Current: 0.79
0.72
44.4
Price/Tangible Book 0.71
DCTH's Price/Tangible Book is ranked higher than
92% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. DCTH: 0.71 )
Ranked among companies with meaningful Price/Tangible Book only.
DCTH' s 10-Year Price/Tangible Book Range
Min: 0.65  Med: 4.77 Max: 44.06
Current: 0.71
0.65
44.06
Price/Median PS Value 0.18
DCTH's Price/Median PS Value is ranked higher than
98% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. DCTH: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
DCTH' s 10-Year Price/Median PS Value Range
Min: 0.18  Med: 1.06 Max: 20
Current: 0.18
0.18
20
Earnings Yield (Greenblatt) (%) 267.60
DCTH's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. DCTH: 267.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DCTH' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 185.6  Med: 293.45 Max: 8625
Current: 267.6
185.6
8625

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DV3.Germany,
Delcath Systems Inc is a Delaware corporation, incorporated on August 5, 1988. The Company is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. It is a specialty pharmaceutical and medical device company developing its proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). In Europe, its proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Its primary focus is on the execution of its clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. Its competitors include Covidian, Biocompatibles, Merit, CeleNova, SirTex, AngioDynamics, and many others. The Company currently holds seven United States patents, ten foreign patents with patent validity in 15 countries, four pending United States patent applications, and two pending foreign patent applications. The Company's products are subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.
» More Articles for DCTH

Headlines

Articles On GuruFocus.com
comment on DCTH Mar 15 2013 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
cooldecency99 note on DCTH May 01 2010 
cooldecency99 note on DCTH May 01 2010 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
DELCATH SYSTEMS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 11 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 10 2015
Delcath Announces Acceptance Of Abstracts For Presentation At The Cardiovascular And Interventional... Jun 09 2015
Delcath to Webcast Management's Presentation at Annual Meeting of Shareholders on June 10, 2015 Jun 05 2015
Delcath to Webcast Management's Presentation at Annual Meeting of Shareholders on June 10, 2015 Jun 05 2015
Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 May 29 2015
Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 May 29 2015
Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer... May 27 2015
Delcath's European Key Opinion Leader Forum On CHEMOSAT Therapy Affirms Benefits To Liver Cancer... May 27 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 26 2015
Delcath Names Dr. Jennifer Simpson President And CEO May 26 2015
Delcath Names Dr. Jennifer Simpson President And CEO May 26 2015
ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open... May 21 2015
ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open... May 21 2015
DELCATH SYSTEMS, INC. Financials May 20 2015
10-Q for Delcath Systems, Inc. May 08 2015
10-K for Delcath Systems, Inc. May 06 2015
Delcath Reports 2015 First Quarter Financial Results May 06 2015
DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report May 06 2015
Delcath Reports 2015 First Quarter Financial Results May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK